CN101085032A - Compound red sage root preparation for treating cardiovascular diseases and its preparation technology - Google Patents
Compound red sage root preparation for treating cardiovascular diseases and its preparation technology Download PDFInfo
- Publication number
- CN101085032A CN101085032A CN 200610031774 CN200610031774A CN101085032A CN 101085032 A CN101085032 A CN 101085032A CN 200610031774 CN200610031774 CN 200610031774 CN 200610031774 A CN200610031774 A CN 200610031774A CN 101085032 A CN101085032 A CN 101085032A
- Authority
- CN
- China
- Prior art keywords
- breviscapine
- active component
- salvianolic acid
- converted
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicinal compound preparation for treating cardiovascular diseases characterized in that, the preparation comprises one of salvia miltiorrhizae or its effective constituent of salvianolic acid, one of Erigeron breviscapus or its effective constituent of Breviscapine, and pharmaceutically acceptable auxiliary materials. The invention also provides a process for preparing the Chinese medicinal composition for treating cardiovascular diseases.
Description
Invention field
The invention belongs to the field of Chinese medicines, relate to a kind of medicine and production technology thereof that is used for the treatment of cardiovascular disease, relate in particular to the medicine that a kind of two flavor principal agents and suitable pharmaceutically useful adjuvant in a kind of and Herba Erigerontis of salviamiltiorrhizabung or its active component salvianolic acid or its active component breviscapine combine, be used for the apoplexy due to the blood stasis yin collaterals, sequela due to the cerebrovascular accident, paralysis and rheumatalgia, coronary heart disease, cardiovascular and cerebrovascular diseases such as myocardial infarction, angina pectoris.
Background technology
Show that according to national statistics the existing hyperpietic of China has reached 100,000,000, annual newly-increased more than 3,000,000.Surplus the existing patients with cerebral apoplexy 500 ten thousand, annual neopathy 1,500,000, dead 200,000; Estimate the existing patients with coronary heart disease about 1,000 ten thousand in the whole nation.Along with the prolongation of people's average expected life-span, China steps into aging society gradually, and the M ﹠ M of cardiovascular and cerebrovascular disease also has the trend that increases year by year.And cardiovascular and cerebrovascular disease, especially the high incidence of apoplexy, myocardial infarction, high mortality, high disability rate not only influence personal health and quality of life, and bring extremely heavy economy and mental burden for country, society and family, if untimely taking some countermeasures, the harm of cardiovascular and cerebrovascular disease will be on the rise.The treatment of cardiovascular and cerebrovascular disease more and more becomes the focus that people pay close attention to.This shows that it is imperative to develop a kind of medicine that can effectively prevent and treat cardiovascular and cerebrovascular disease.
The Western medicine toxic and side effects that is used for the treatment of cardiovascular and cerebrovascular disease of having gone on the market at present is bigger, and untoward reaction is more, and as cilostazol etc., because cardiovascular and cerebrovascular disease need take medicine for a long time, and China patient more is ready to take the Chinese medicine of determined curative effect, safety non-toxic mostly.Still will invent a kind of effective Chinese medicine composition that will be used for the treatment of cardiovascular and cerebrovascular disease, the medicine that combines by a kind of two flavor principal agents in a kind of and Herba Erigerontis of Radix Salviae Miltiorrhizae or its active component salvianolic acid or its active component breviscapine and suitable pharmaceutically useful adjuvant, because the single preparation of the two all has determined curative effect through clinical verification for many years, the characteristics that toxic and side effects is little, after deliberation, we with the two organic assembling after, to obtain the good clinical curative effect, so this medicine in case study successfully will bring glad tidings for vast cardiovascular and cerebrovascular disease patient and produce huge social and economic benefit.
Summary of the invention
Purpose of the present invention aims to provide the Chinese traditional compound medicine that is used for the treatment of cardiovascular disease of the reliable and steady quality safety of a kind of determined curative effect, tool expelling cold and relieving exterior syndrome, expelling wind and removing dampness, promoting blood circulation to remove obstruction in the collateral, the effect of eliminating stasis to stop pain.Be used for the apoplexy due to the blood stasis yin collaterals, sequela, paralysis and rheumatalgia, coronary heart disease due to the cerebrovascular accident, cardiovascular and cerebrovascular diseases such as angina pectoris.
Another object of the present invention aims to provide the preparation method of above-mentioned herbal mixture.
The objective of the invention is to realize by following manner:
The effective medicinal component of the present composition is by a kind of and Herba Erigerontis of salviamiltiorrhizabung or its active component salvianolic acid or a kind of composition the in its active component breviscapine.
The active component salvianolic acid of Radix Salviae Miltiorrhizae comprises saivianic acid A, second, the third in the present composition, protocatechualdehyde, one or more compositions in the danshensu.
Development test shows that described principal agent is formulated by following weight ratio: salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 5～95% and breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 95～5%.
Described principal agent can also be formulated by following weight ratio: salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 20～80% and breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 80～20%.
Described principal agent is also formulated by following weight ratio: salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 30～70% and breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 70～30%.
Especially be that salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 35% is good with breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 65% with the two ratio.
The present composition can be with the oral preparation of Chinese traditional medicinal of effective medicinal ingredient and medicine acceptable adjuvant composition, injection etc.
Herba Erigerontis tool expelling cold and relieving exterior syndrome, expelling wind and removing dampness, the effect of activating collaterals to relieve pain, modern owing to it has the restriction infarction size, improves ischemic myocardium, prevents the generation of pump failure and the effect of development, it is classified as blood vessel dilating class medicine.Breviscapine is an isolated flavone constituents from Herba Erigerontis, be mainly scutellarin, pharmacological research proves, breviscapine has the cerebral blood flow increasing amount, reduces cerebral vascular resistance, improves cerebral circulation, alleviates the arteriole spasm, improves effects such as blood-brain barrier permeability, antagonism myocardial ischemia reperfusion injury, is that Herba Erigerontis is used for the treatment of the active component of paralysing due to the cerebrovascular disease.The effect and Radix Salviae Miltiorrhizae tool activating blood and removing stasis, pain relieving are calmed the nerves etc. is used for angina pectoris, lumps in the chest and abdomen, palpitation with fear sleeplessness etc.By the internal medicine blood stasis hot person that holds concurrently is used always.Modern Chinese medicine is got its stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, and the effect of the relieving restlessness that clears away heart-fire is used for sick treatments such as cardiovascular and cerebrovascular vessel.The water solublity active component of Radix Salviae Miltiorrhizae is a salvianolic acid.
Chinese medicine thinks that the capable then blood of gas is capable, and the stagnation of QI is blood stasis then, and with arteriole, venous congestion in the modern medicine, erythrocytic thickness and platelet aggregation rising cause the pathology of slow blood flow, microcirculation disturbance consistent.Based on above-mentioned principle, we select the Radix Salviae Miltiorrhizae of effects such as having activating blood and removing stasis, removing heat from blood nourishes blood, pain relieving is calmed the nerves and have expelling cold and relieving exterior syndrome, and the Herba Erigerontis of expelling wind and removing dampness effect is compatible, and expelling cold and relieving exterior syndrome is played in tonification mutually altogether, wind-expelling pain-stopping, the effect of active dissipating blood stasis.
The oral effective daily dose of the present invention is salvianolic acid 5～15mg:: breviscapine 15～30mg, every day 1～3 time.
The specific embodiment
Embodiment 1:
Take by weighing salvianolic acid 5g and breviscapine 10g respectively, add supplementary product starch, microcrystalline Cellulose, sodium lauryl sulphate, sucrose etc., be mixed, granulate, granulate, drying, tabletting is prepared into 1000 in tablet.
Embodiment 2:
Take by weighing salvianolic acid 3g and Herba Erigerontis 300g respectively, be prepared into capsule as follows:
A, take by weighing Herba Erigerontis in proportion, add 10 times of decoctings and boil 3 times, each 0.5h, it is 1.10 (50 ℃) that decoction liquor is concentrated into relative density, adds ethanol and makes that to contain alcohol amount be 55%, stirs, place, filter, decompression filtrate recycling ethanol is to relative density 1.10 (50 ℃), with hydrochloric acid adjust pH to 2, in 55 ℃ of insulation 6h, filter, recrystallization, vacuum drying are promptly.
B, A gained breviscapine is pulverized, pulverized, be mixed, add corresponding auxiliary material pregelatinized Starch, tween 80, magnesium stearate, hydroxy methocel etc., granulate with the salvianolic acid that takes by weighing in proportion, granulate, mixing, drying, fill is to common gelatine capsule.Be prepared into 1000 of capsules.
Embodiment 3
Take by weighing danshensu 2g respectively, Herba Erigerontis 50g, method by embodiment 2 obtains breviscapine with the Herba Erigerontis extraction, and with danshensu and breviscapine pulverizing mix homogeneously, add water for injection 15ml, make it dissolving, the medicinal sodium chloride that adds 0.8g, shake up dissolving, add an amount of benzyl alcohol, sodium sulfite etc., the pH of an amount of regulator solution of hydro-oxidation sodium is between 4.5～5.0, and add water to 1000ml, stir evenly, filtration is sub-packed in the 5ml neutral density glass container, with 100 ℃ of sterilizations in 45 minutes of flowing steam.
Claims (6)
1, a kind of compound Chinese medicinal preparation that is used for the treatment of cardiovascular disease is characterized in that: be made up of a kind of this two flavor principal agent and medicine acceptable auxiliary in a kind of and Herba Erigerontis in Radix Salviae Miltiorrhizae or its active component salvianolic acid or its active component breviscapine.
2, a kind of compound Chinese medicinal preparation that is used for the treatment of cardiovascular disease according to claim 1 is characterized in that: described two flavor principal agents are formulated by following weight ratio: salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 5～95% and breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 95～5%.
3, a kind of compound Chinese medicinal preparation that is used for the treatment of cardiovascular disease according to claim 1 is characterized in that: described two flavor principal agents are formulated by following weight ratio: salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 20～80% and breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 80～20%.
4, a kind of compound Chinese medicinal preparation that is used for the treatment of cardiovascular disease according to claim 1 is characterized in that: described two flavor principal agents are formulated by following weight ratio: salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 30～70% and breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 70～30%.
5, a kind of compound Chinese medicinal preparation that is used for the treatment of cardiovascular disease according to claim 1 is characterized in that: described two flavor principal agents are formulated as good by following weight ratio: salvianolic acid (Radix Salviae Miltiorrhizae can be converted the amount for its active component salvianolic acid) 35% and breviscapine (Herba Erigerontis can be converted the amount into its active component breviscapine) 65%.6, according to each described a kind of compound Chinese medicinal preparation that is used for the treatment of cardiovascular disease of claim 1-5, it is characterized in that described principal agent and medicine acceptable auxiliary make compound Chinese medicinal preparation, comprise oral formulations, injection etc.
7, a kind of compound Chinese medicinal preparation that is used for the treatment of cardiovascular disease according to claim 6, described principal agent and medicine acceptable auxiliary are made oral formulations, as tablet, capsule or oral liquid etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610031774 CN101085032A (en) | 2006-06-06 | 2006-06-06 | Compound red sage root preparation for treating cardiovascular diseases and its preparation technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610031774 CN101085032A (en) | 2006-06-06 | 2006-06-06 | Compound red sage root preparation for treating cardiovascular diseases and its preparation technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101085032A true CN101085032A (en) | 2007-12-12 |
Family
ID=38936316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610031774 Pending CN101085032A (en) | 2006-06-06 | 2006-06-06 | Compound red sage root preparation for treating cardiovascular diseases and its preparation technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101085032A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107137410A (en) * | 2017-06-08 | 2017-09-08 | 中国人民解放军第四军医大学 | A kind of Compound Chinese Herbal Monomer Recipe compatibility agent and preparation method for being used to treat cerebral ischemia |
-
2006
- 2006-06-06 CN CN 200610031774 patent/CN101085032A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107137410A (en) * | 2017-06-08 | 2017-09-08 | 中国人民解放军第四军医大学 | A kind of Compound Chinese Herbal Monomer Recipe compatibility agent and preparation method for being used to treat cerebral ischemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101347528B (en) | Chinese medicinal composition for resisting cardiovascular and cerebrovascular diseases | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN103083582B (en) | Medicine for treating hyperlipidemia | |
| CN1733031A (en) | Brain caring oral liquid and its preparation process | |
| CN101085032A (en) | Compound red sage root preparation for treating cardiovascular diseases and its preparation technology | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN102343049A (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN101084965A (en) | Safflower compound preparation and its preparation technology | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| CN104000871A (en) | Drug for treating myocardial ischemia | |
| CN104001026A (en) | Medicine for treating myocardial ischemia | |
| CN110464803A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood pressure | |
| CN109925399B (en) | Compound traditional Chinese medicine composition for treating coronary heart disease and angina pectoris and preparation method thereof | |
| CN103055122A (en) | Medicine for preventing restenosis after intracoronary stent implantation and preparation method thereof | |
| CN107913315A (en) | A kind of Chinese medicine composition for treating refractory hypertension and preparation method thereof | |
| CN103432200B (en) | A kind of medicine for the treatment of Orthopeadic Surgery disease | |
| CN100435842C (en) | Chinese-medicinal preparation for treating hypertension and its making method | |
| CN106620070A (en) | Medicinal composition for treating osteoarthropathy and preparation method and application thereof | |
| CN105832934A (en) | Traditional Chinese medicine for treating hypertension | |
| CN105031364A (en) | Preparation for preventing and treating toothache due to wind-fire evil and preparation method of preparation | |
| CN1853711A (en) | Xinmaikangzhong Chinese medicinal composition and preparation thereof | |
| CN101700271B (en) | Traditional Chinese medicine preparation for treating apoplexy sequelae | |
| CN106138795A (en) | Chinese medicine composition for the treatment of premature beat and preparation method thereof | |
| CN103961677A (en) | Traditional Chinese medicine mixture for treating arrhythmia | |
| CN101461875B (en) | Chinese medicinal composition for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |